CINECA IRIS Institutional Research Information System

RIGHI, Luisella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.813
EU - Europa 4.640
AS - Asia 2.797
SA - Sud America 127
OC - Oceania 95
AF - Africa 66
Continente sconosciuto - Info sul continente non disponibili 5
Totale 15.543
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.666
IT - Italia 1.670
CN - Cina 1.357
SG - Singapore 492
IE - Irlanda 470
SE - Svezia 416
DE - Germania 374
FR - Francia 324
FI - Finlandia 201
UA - Ucraina 200
JP - Giappone 194
GB - Regno Unito 184
KR - Corea 155
AT - Austria 141
PL - Polonia 133
IN - India 130
VN - Vietnam 118
CA - Canada 106
ES - Italia 104
NL - Olanda 88
AU - Australia 84
TR - Turchia 82
ID - Indonesia 81
BR - Brasile 68
BE - Belgio 59
HK - Hong Kong 57
DK - Danimarca 37
GR - Grecia 37
MX - Messico 37
TW - Taiwan 37
RU - Federazione Russa 35
RO - Romania 29
CH - Svizzera 28
IL - Israele 24
SN - Senegal 23
AR - Argentina 21
NO - Norvegia 21
CO - Colombia 19
HU - Ungheria 17
CZ - Repubblica Ceca 14
TH - Thailandia 10
NZ - Nuova Zelanda 9
PH - Filippine 9
RS - Serbia 9
MA - Marocco 8
PT - Portogallo 8
ZA - Sudafrica 8
MY - Malesia 7
SA - Arabia Saudita 7
SI - Slovenia 7
UZ - Uzbekistan 7
BY - Bielorussia 6
CL - Cile 6
IR - Iran 6
DZ - Algeria 5
EG - Egitto 5
EU - Europa 5
LU - Lussemburgo 5
PE - Perù 5
BG - Bulgaria 4
NG - Nigeria 4
SK - Slovacchia (Repubblica Slovacca) 4
BW - Botswana 3
EC - Ecuador 3
LB - Libano 3
MK - Macedonia 3
PK - Pakistan 3
SY - Repubblica araba siriana 3
TN - Tunisia 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
EE - Estonia 2
HN - Honduras 2
HR - Croazia 2
IQ - Iraq 2
LT - Lituania 2
LV - Lettonia 2
PS - Palestinian Territory 2
PY - Paraguay 2
SC - Seychelles 2
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
CY - Cipro 1
FJ - Figi 1
GT - Guatemala 1
IS - Islanda 1
KE - Kenya 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MG - Madagascar 1
MM - Myanmar 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
MW - Malawi 1
OM - Oman 1
PG - Papua Nuova Guinea 1
TG - Togo 1
Totale 15.543
Salva come PNG Salva come JPEG
Città #
Chandler 687
Houston 600
Beijing 565
Dublin 459
Fairfield 453
Torino 413
Singapore 369
Ann Arbor 361
Wilmington 304
Ashburn 291
Woodbridge 255
Seattle 224
Redwood City 212
Cambridge 172
Nyköping 160
Villeurbanne 154
Turin 153
Columbus 140
Pisa 137
Santa Clara 133
Princeton 132
Vienna 132
Dearborn 130
Medford 130
Fremont 124
Jacksonville 122
Warsaw 91
Milan 89
Shanghai 79
New York 74
Boston 73
Guangzhou 72
Jakarta 71
Dong Ket 61
Tokyo 61
Nanjing 58
Hangzhou 49
San Diego 47
Boardman 46
Rome 44
Brussels 42
Düsseldorf 39
Munich 37
Honolulu 36
Seoul 35
Piemonte 32
Helsinki 29
London 28
Kunming 26
Taipei 26
Hefei 25
Ottawa 25
Chicago 24
Madrid 24
Changsha 23
Phoenix 23
Jinan 22
Silver Spring 22
Washington 22
Wuhan 22
Chengdu 21
Pune 21
Chongqing 20
Istanbul 20
Falls Church 19
Zhengzhou 19
Dallas 18
Norwalk 18
Shenyang 18
Toronto 18
Osaka 17
Central District 16
Hebei 16
Upper Marlboro 16
Mountain View 15
Napoli 14
Paris 14
Verona 14
Adelaide 13
Berlin 13
Buffalo 13
Hong Kong 13
Lexington 13
Redmond 13
Renton 13
Sydney 13
Tianjin 13
Zurich 13
Birmingham 12
Bologna 12
Canberra 12
Changchun 12
Duncan 12
Los Angeles 12
Senigallia 12
Barcelona 11
Las Vegas 11
León 11
Rotterdam 11
Arezzo 10
Totale 9.071
Salva come PNG Salva come JPEG
Nome #
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma 1.034
What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms? 588
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 468
Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied 467
Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer? 449
Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas 385
Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study 319
Mesothelioma families without inheritance of a BAP1 predisposing mutation 307
Detection of EGFR mutations in archival lung cancer samples by pyrosequencing 306
Therapeutic Biomarkers in Lung Neuroendocrine Neoplasia 298
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 271
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. 266
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 254
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma 253
Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. 252
Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma 230
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 225
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. 222
Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy 211
An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation 191
Brca1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: a Large Retrospective Study 190
Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. 189
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. 185
Il tumore fibroso solitario della pleura: una serie di 35 casi trattati chirurgicamente 181
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma 179
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing 179
Role of surgical resection in colorectal lung metastases: analysis of 137 patients. 175
Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research. 158
Classification of pulmonary neuroendocrine tumors: New insights 142
Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression 141
Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. 135
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 134
Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma 130
Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era 129
Thymidylate synthase expression in large cell carcinoma ofthe lung 123
Clinical and biological significance of CD157 in malignant pleural mesothelioma 122
Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases 117
Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma 114
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung 114
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Apr 29 113
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 113
CD157 is a novel prognostic marker of malignant pleural mesothelioma involved in the control of tumor aggressiveness 110
Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase–Positive Lung Cancer Patient: Adverse Event or Disease Spread? 110
Human renal angiomyolipoma cells of male and female origin can migrate and are influnced by microenvironmental factors 109
IκBα targeting promotes oxidative stress-dependent cell death 109
Updates on lung neuroendocrine neoplasm classification 106
Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung 106
A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer 103
Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes 98
Identification of MicroRNAs Differentially Expressed in Lung Carcinoid Subtypes and Progression 94
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 89
Solitary Fibrous Tumours of the Pleura 89
[Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.] 88
Tumor/Stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis 84
Multiple Assays to Determine Methylguanine-Methyltransferase Status in Lung Carcinoids and Correlation with Clinical and Pathological Features 84
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-from morphology to molecular testing 83
EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer 83
Diffusion-weighted quantitative MRI of pleural abnormalities: Intra- and interobserver variability in the apparent diffusion coefficient measurements 83
Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma 82
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy 81
Expression of the neuroendocrine phenotype in carcinomas of the breast. 80
Evaluation of the preclinical efficacy of lurbinectedin in malignant pleural mesothelioma 80
Clinical and molecular features of epidermal growth factor receptor (Egfr) mutation positive non‐small‐cell lung cancer (nsclc) patients treated with tyrosine kinase inhibitors (tkis): Predictive and prognostic role of co‐mutations 80
A new prognostic score in patients with malignant pleural mesothelioma. 80
Changes in prostatic cancer at radical prostatectomy during the prostate specific antigen era: an Italian experience 78
34betaE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast. 77
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. 77
Helical-Tip Needle for Transthoracic Percutaneous Image-Guided Biopsy of Lung Tumors: Results of a Pilot Prospective Comparative Study with a Standard Tru-Cut Needle 77
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 76
Future perspectives from lung cancer pre-clinical models: new treatments are coming? 76
Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice 75
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 74
Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data 73
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design 73
Clinical significance of neuroendocrine carcinoma of the breast. 72
INCREASED NUMBER OF NEUROENDOCRINE CELLS IN METASTATIC COLORECTAL ADENOCARCINOMA FOLLOWING CHEMO/RADIOTHERAPY 72
Structural, functional and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum 71
Evaluation of Innate Immune Mediators Related to Respiratory Viruses in the Lung of Stable COPD Patients 71
Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective 70
SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma 70
Plasma and Tissue Inflammatory and Angiogenic Biomarkers to Explore Resistance to EGFR-TKIs and Association with VeriStrat Status: Topic: EGFR Biomarkers 68
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. 68
Role of surgical resection in colorectal lung metastases: analysis of 137 patients 66
Expression analysis of genes involved in DNA repair or synthesis in mixed neuroendocrine/nonneuroendocrine carcinomas 66
Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. 66
Prognostic significance of osteopontin expression in malignant pleural mesothelioma 65
Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms 64
Mammalian target of rapamycin (MTOR) signaling activation patterns in neuroendocrine tumors of the lung 62
DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics 62
Repositioning PARP inhibitors in the treatment of thoracic malignancies 61
NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images 58
Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. 57
Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. 57
Gross Specimen Handling Procedures Do Not Impact the Occurrence of Spread through Air Spaces (STAS) in Lung Cancer 56
Pathological characterization of tumor immune microenvironment (Time) in malignant pleural mesothelioma 56
Expression and pharmacological inhibition of thymidilate synthase and Src kinase in non-small cell lung cancer. 55
Mesotelioma pleurico maligno: caratteristiche clinico-patologiche e fattori prognostici in una serie di 517 pazienti 54
ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization 54
Prognostic Role of Bone Sialoprotein in Clear Cell Renal Carcinoma 52
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges 52
Totale 14.551
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.721
article - articoli 0
book - libri 0
conference - conferenze 3.760
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.481
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.722 0 0 0 0 214 429 246 192 218 185 124 114
2020/20211.899 113 135 149 150 187 151 123 138 191 168 145 249
2021/20221.969 141 113 111 152 93 102 103 124 81 144 451 354
2022/20232.395 240 182 67 216 219 544 168 179 297 56 135 92
2023/20241.369 153 224 78 94 85 158 78 62 15 113 141 168
2024/20251.289 86 304 194 315 390 0 0 0 0 0 0 0
Totale 16.065